Company Overview
AscentX Medical is a privately held Medical Technology Company focused on the clinical development and marketing of novel, minimal-invasive endoscopic injection procedures designed to address unmet medical needs amongst both patients and physicians and help cure various debilitating and socially isolating medical conditions of the growing aging population.
The Company believes that its proprietary technology platform, once approved for clinical use, has the potential to create new standards of care via its respective procedures, as they are designed to provide safer, more user-friendly, least-invasive, curative, and more cost-effective outpatient treatments.
The Company was founded by the original team that created ArteFill®, the first and only FDA-approved permanent injectable wrinkle filler in the United States (October 2006). ArteFill’s U.S. market approval has paved the way for additional medical applications utilizing similar injectable PMMA microsphere technology in order to address several prevalent and debilitating medical conditions caused by sphincter muscle incompetence and spinal disc degeneration.
For that purpose, after more than 25 years of research & development, the AscentX team has developed a specifically designed, proprietary, next-generation injectable biomaterial platform to permanently expand soft tissues via injection procedures and for this purpose exclusively licensed U.S. Patent # 8,586,089 (issued November 2013) and pending international patents for the indications of Gastro-esophageal Reflux Disease (GERD), Facial Wrinkles and Scars, and Degenerative Disc Disease (DDD).
The Company's treatment concept of permanent injectable soft tissue augmentation/reinforcement, also known as 'soft tissue bulking', has the potential to address and cure a variety of other prevalent medical conditions including Stress Urinary Incontinence (SUI) and Fecal Incontinence (FI), as they share a common underlying cause: sphincter muscle incompetence accompanied by loss of sphincter tone.
We believe, based on our extensive collective experience in injectable soft tissue augmentation, that above medical conditions described on our website can be cured safely, cost-effectively and least-invasive via injectable 'soft tissue engineering'.
Our Mission
- Benefit the Aging Population through least-invasive, outpatient-based, and cost-effective curative Injection Procedures
- Restore Patients’ Quality of Life and become the Global Leader in 'Permanent Injectable Soft Tissue Repair' by the end of 2021
Our Vision
- Become the Global Leader in ‘Permanent Injectable Soft Tissue Repair’ to cure various debilitating Medical Conditions affecting the growing Aging Population
- Build a Company and Products that will have a lasting Impact on Global Healthcare
- Become a disruptive ‘Force of Change’ in GERD, Dermal Fillers, and Spinal Disc Repair
Our Values
- CULTURE OF CARE
- INTEGRITY
- PATIENT-CENTRICITY
- INNOVATION
Our Near-Term Goals
- Improve Patients’ Quality of Life by creating a new ‘Standard of Care’ for Gastro-Esophageal Reflux Disease (GERD) through least-invasive endoscopic Injection Treatment by 2023
- Challenge the ‘Status Quo’ in GERD Treatment and pioneer a new, potentially game-changing, cost-effective outpatient-based Procedure to obviate the need for life-long Medication and reduce the Risk of Esophageal Cancer (“Curative Endoscopic Injection”)
- Become the leading Technology and Solution Provider of safe, cost-effective and user-friendly Injection Bulking Technologies as the future first-line Treatment to cure various age-related and debilitating Medical Conditions, including GERD, Spinal Disc Degeneration, and Facial Wrinkles and Scars
